Drug Approval | May 12, 2022
USFDA approves Lilly and Incyte's Olumiant to treat hospitalised patients with Covid-19
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
Takeda and United Nations Global Compact Network of India (UNGCNI) join hands
There is a need for the Ministry of Health to put it on the priority list and address the issues, which are numerous
RNAstorm and DNAstorm RNA/DNA extraction kits will be sold exclusively through the Biotium website and authorized distributors
The research was funded by the National Institutes of Health, the Eversight Center for Vision and Eye Banking Research, and Research to Prevent Blindness
The research was supported by the BGU Coronavirus Challenge and the Israeli Ministry of Health.
CIVCO RT will also display its recent innovations focusing on improving patient comfort and outcomes
As an industrial partner of the IHU, the Medi-Globe Group is thus further expanding its role as an innovation leader in minimally invasive diagnostics and therapies
Subscribe To Our Newsletter & Stay Updated
